Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Malkin

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Neurology and Neuroscience Reports|May 10, 2007
Environmental risk factors for brain tumorsJennifer M Connelly, Mark G Malkin
Frontiers in Cell and Developmental Biology|June 20, 2022
tRNA Function and Dysregulation in CancerTania Gupta, Mark G Malkin, Suyun Huang
Neurology|August 12, 2004
Leptomeningeal and ependymal invasion by glioblastoma multiformeMartin Begemann, A John Tsiouris, Mark G Malkin
The Clinical Neuropsychologist|March 22, 2016
Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Review and Neuropsychological Case StudyAshlee R Loughan, Aislyn Allen, Robert Perna, et al.
Neuro-Oncology|July 29, 2004
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapyJeffrey J Raizer, Mark G Malkin, Martin Kleber, et al.
Cancer|August 12, 2004
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinomaRose Lai, Chau T Dang, Mark G Malkin, et al.
Journal of Neuro-Oncology|October 9, 2009
Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebriBenjamin M Ellingson, Scott D Rand, Mark G Malkin, et al.
Seminars in Neurology|September 26, 2023
Disease-Based Prognostication: Neuro-OncologyKristin A Waite, Gino Cioffi, Mark G Malkin, et al.
Neuro-Oncology|January 5, 2002
A phase II study of extended low-dose temozolomide in recurrent malignant gliomasRaja B Khan, Jeffrey J Raizer, Mark G Malkin, et al.
Investigational New Drugs|October 21, 2006
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumorsLuis H Camacho, Jon Olson, William P Tong, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Neurology and Neuroscience Reports|May 10, 2007
Environmental risk factors for brain tumorsJennifer M Connelly, Mark G Malkin
Frontiers in Cell and Developmental Biology|June 20, 2022
tRNA Function and Dysregulation in CancerTania Gupta, Mark G Malkin, Suyun Huang
Neurology|August 12, 2004
Leptomeningeal and ependymal invasion by glioblastoma multiformeMartin Begemann, A John Tsiouris, Mark G Malkin
The Clinical Neuropsychologist|March 22, 2016
Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Review and Neuropsychological Case StudyAshlee R Loughan, Aislyn Allen, Robert Perna, et al.
Neuro-Oncology|July 29, 2004
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapyJeffrey J Raizer, Mark G Malkin, Martin Kleber, et al.
Cancer|August 12, 2004
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinomaRose Lai, Chau T Dang, Mark G Malkin, et al.
Journal of Neuro-Oncology|October 9, 2009
Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebriBenjamin M Ellingson, Scott D Rand, Mark G Malkin, et al.
Seminars in Neurology|September 26, 2023
Disease-Based Prognostication: Neuro-OncologyKristin A Waite, Gino Cioffi, Mark G Malkin, et al.
Neuro-Oncology|January 5, 2002
A phase II study of extended low-dose temozolomide in recurrent malignant gliomasRaja B Khan, Jeffrey J Raizer, Mark G Malkin, et al.
Investigational New Drugs|October 21, 2006
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumorsLuis H Camacho, Jon Olson, William P Tong, et al.
Pageof 3